What's Going On With Enveric Biosciences Stock On Friday?

Enveric Biosciences (NASDAQ: ENVB) stock surged nearly 30% after the FDA outlined steps to accelerate the development of serotonin-2A agonists and psychedelic-based therapies for mental health disorders. The FDA cleared the first U.S. trial for an ibogaine derivative to treat alcohol use disorder and will issue national priority vouchers to companies studying psychedelic compounds. This proactive stance follows a White House directive and focuses on fast-tracking promising treatments, especially those with Breakthrough Therapy designation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin